---
layout: default
title: Rasagiline
parent: AI Predictions (L5)
nav_order: 492
evidence_level: L5
indication_count: 10
---

# Rasagiline
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using no skill — this is a direct, fully-specified content-generation task (report template already given verbatim); no coding/debugging/brainstorming applies.

# Rasagiline: From Parkinson's Disease to PLA2G6-Associated Neurodegeneration

## One-Sentence Summary

> Rasagiline is a selective monoamine oxidase-B (MAO-B) inhibitor originally used for **Parkinson's disease**.
> The TxGNN model predicts it may be effective for **PLA2G6-Associated Neurodegeneration**,
> but this direction is currently supported by **0 clinical trials** and **0 publications**, and the underlying rationale itself flags the link as likely a knowledge-graph artifact rather than a true mechanistic signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Parkinson's disease (referenced in the repurposing rationale; not confirmed via EU license data, as the drug is not marketed in the EU) |
| Predicted New Indication | PLA2G6-Associated Neurodegeneration |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in DrugBank for this evidence pack (flagged as a High-severity data gap). Based on information embedded in the evidence pack's own repurposing rationales for other candidates, Rasagiline is known to act as an irreversible, selective MAO-B inhibitor, reducing dopamine breakdown and providing antioxidant/neuroprotective effects — the basis for its established use in Parkinson's disease.

PLA2G6-associated neurodegeneration, however, is a distinct disease entity: a PLA2G6 enzyme defect causing abnormal phospholipid metabolism, leading to infantile neuroaxonal dystrophy through lipid peroxidation and iron accumulation. This pathway has no established overlap with MAO-B–mediated dopamine metabolism or antioxidant signaling.

The evidence pack's own mechanistic assessment is explicit on this point: the high TxGNN score for this candidate "may reflect a clustering effect among 'neurodegenerative disease' nodes in the knowledge graph rather than true mechanistic specificity." In other words, the score is likely driven by graph-topological proximity between neurodegenerative disease nodes, not a genuine pharmacological rationale — which is why no clinical trials or literature have emerged to support it.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## EU Market Information

No EU marketing authorization records found — Rasagiline is currently **not marketed** under this evidence pack's regulatory data (0 authorizations on file).

## Safety Considerations

Please refer to the SmPC for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (PLA2G6-associated neurodegeneration) has no supporting clinical trials or literature, and the mechanistic rationale itself is assessed as weak — most likely a knowledge-graph clustering artifact rather than a genuine pharmacological signal. There is no basis to advance this specific indication at this time.

**To proceed, the following is needed:**
- Confirmed MOA data via DrugBank API (currently a High-severity data gap, DG002)
- TFDA/SmPC-equivalent label warnings and contraindications (currently a Blocking data gap, DG001 — required before any S1 safety screening)
- Preclinical/mechanistic studies directly linking MAO-B inhibition to PLA2G6-related lipid peroxidation/iron-deposition pathways, if this candidate is to be pursued further

**Note:** Among the 10 predicted indications in this pack, **Lewy body dementia** (rank 8, L3, "Research Question" stage) shows substantially stronger support — an α-synuclein/MAO-B mechanistic link, exploratory Phase 2 biomarker trials in related dementias, and multiple preclinical papers — and may warrant separate evaluation as a more credible repurposing candidate than the top-ranked prediction discussed above.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

